2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176143
    P2Y1/P2Y6 antagonist 1 98%
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-176146
    Keap1/Nrf2/ARE activator 1 98%
    Keap1/Nrf2/ARE activator 1 (compound HT-3) is a Keap1/Nrf2/ARE pathway activator. Keap1/Nrf2/ARE activator 1 exhibits antioxidant activity and neuroprotective efficacy.
    Keap1/Nrf2/ARE activator 1
  • HY-176180
    PROTAC STING degrader-4 98%
    PROTAC STING degrader-4 is a nitro-free covalent STING PROTAC degrader with a DC50 of 3.23 μM. PROTAC STING degrader-4 effectively inhibits STING as well as its downstream signaling, such as p-TBK1 and p-NF-κB (p-P65), and immune-inflammatory cytokines. PROTAC STING degrader-4 mitigates kidney and blood inflammation in Cisplatin (HY-17394)-induced acute kidney injury (AKI) mice model. Pink: STING ligand (HY-176183); Blue: CRBN ligase ligand (HY-103596); Black: linker (HY-176182); CRBN ligase ligand + linker: HY-176181
    PROTAC STING degrader-4
  • HY-176181
    Thalidomide-4-PEG4-OTs 3023389-80-9 98%
    Thalidomide-4-OH-PEG4-OTs is an E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based CRBN ligand (HY-103596) and 4-unit PEG linker (HY-176182). Thalidomide-4-OH-PEG4-OTs can be used for synthesis of PROTAC STING degrader-4 (HY-176180).
    Thalidomide-4-PEG4-OTs
  • HY-176182
    Br-C2-PEG3-OTs 2757925-36-1 98%
    Br-C2-PEG3-OTs is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC STING degrader-4 (HY-176180).
    Br-C2-PEG3-OTs
  • HY-176183
    STING ligand-4
    STING ligand-4 (Compound 2) is a nitro-free covalent STING inhibitor with an IC50 < 0.2 μM. STING ligand-4 can be used for synthesis of PROTAC STING degrader-4 (HY-176180).
    STING ligand-4
  • HY-17618A
    Rac-Pemafibrate 848258-31-1 98%
    Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate
  • HY-176194
    Antifibrotic agent 1 98%
    Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model.
    Antifibrotic agent 1
  • HY-176212
    Ferroptosis-IN-20 98%
    Ferroptosis-IN-20 (Compound 34a) is a Ferroptosis inhibitor (EC50: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe2+ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI).
    Ferroptosis-IN-20
  • HY-176218
    TTTE
    TTTE is a sulfone bischalcone derivative. TTTE has major anti-necrotic, anti-inflammatory and anti-fibrotic activities. TTTE exerts regulatory effects by downregulating key molecules such as Caspase-3, TNF-α, NF-κB and TGF-β. TTTE can be used in the study of liver injury.
    TTTE
  • HY-176222
    IRF1 antagonist 1
    IRF1 antagonist 1 (8003-3282) is a potent IRF1 (interferon regulatory factor) antagonist with anti-inflammatory activity. IRF1 antagonist 1 can maintain blood-brain barrier integrity and reduce brain edema. IRF1 antagonist 1 can improve neurological outcomes in an acute traumatic brain injury (TBI) mouse model.
    IRF1 antagonist 1
  • HY-176224
    Anti-virulence factor-IN-2 98%
    Anti-virulence factor-IN-2 (compound C7) is an inhibitor targeting the virulence factor KpsM in Escherichia coli. kpsM mediates the translocation of capsular polysaccharides to the cell surface, allowing kpsM-positive E. coli to escape the phagocytosis of the scavenger receptor Marco on liver Kupffer cells, leading to bacterial dissemination. kpsM-positive E. coli exacerbates ethanol-induced liver disease. Anti-virulence factor-IN-2 can inhibit the ethanol-induced liver disease model caused by kpsM-dependent capsid in mice and has anti-infective activity. Anti-virulence factor-IN-2 can be used for the study of alcoholic hepatitis.
    Anti-virulence factor-IN-2
  • HY-176234
    PDE4-IN-28 98%
    PDE4-IN-28 (Compound G1) is a PDE4D inhibitor (IC50: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC50: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing.
    PDE4-IN-28
  • HY-176243
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester 1947405-90-4
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester is a derivate of 15-Deoxy-Δ-12,14-prostaglandin J2 (HY-108568). 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester
  • HY-176248
    Dimephosphon 14394-26-4
    Dimephosphon is an anti-inflammatory agent with antihistamine and antiserotonin activities. Dimephosphon helps maintain the conduction function of the spinal cord and reduces the excitability of spinal motor neurons in the area surrounding the lesion. Dimephosphon directly activates lymphatic vessel movement and improves lymphatic circulation. Dimephosphon can be used for the study of inflammatory edema, acute spinal cord injury and lymphatic circulation disorders.
    Dimephosphon
  • HY-176251
    CBP/p300-IN-22 98%
    CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4(1). CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions.
    CBP/p300-IN-22
  • HY-176255
    TBK1 degrader-4 98%
    TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD).
    TBK1 degrader-4
  • HY-176265
    DDS5 2871481-31-9 98%
    DDS5 is a CD28 inhibitor with a kd of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC50: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis.
    DDS5
  • HY-176273
    RORγt inverse agonist 35
    RORγt inverse agonist 35 (Compound 22) is a RORγt inverse agonist with an IC50 of 1.51 μM. RORγt inverse agonist 35 significantly inhibits Th17 differentiation and proinflammatory properties in human CD4+ T cells. RORγt inverse agonist 35 can be used for research of Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).
    RORγt inverse agonist 35
  • HY-176274
    FASN/SCD-IN-1 98%
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
    FASN/SCD-IN-1
Cat. No. Product Name / Synonyms Application Reactivity